EVG.L实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 23:24):

Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases...

Stats
今日成交量	10.75M
平均成交量	1.25M
市值	3.42M
EPS	£0 ( 2024-04-19 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-0.800
ATR14	£0 (0.00%)

Evgen Pharma PLC 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Evgen Pharma PLC 财务报表

Annual	2022
营收:	£442 000
毛利润:	£429 000 (97.06 %)
EPS:	£-0.0147

FY	2022
营收:	£442 000
毛利润:	£429 000 (97.06 %)
EPS:	£-0.0147

FY	2022
营收:	£0
毛利润:	£0 (0.00 %)
EPS:	£-0.00990

FY	2021
营收:	£194 000
毛利润:	£0.00 (0.00 %)
EPS:	£-0.0279

Financial Reports:

No articles found.

Evgen Pharma PLC

Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. It develops its products using Sulforadex, a sulforaphane stabilization technology. The company's lead product is SFX-01, that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma, as well as in preclinical stage for the treatment of haematological malignancies and analogues. It also provides out-licensing of its technology services. Evgen Pharma plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.